Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges

Allogene Therapeutics (ALLO) has disclosed a new risk, in the Economy & Political Environment category.

Allogene Therapeutics faces significant risks due to evolving political, trade, and regulatory developments, particularly following the U.S. government’s announcement of new tariffs in 2025. These tariffs, which include a baseline of 10-15% and country-specific rates as high as 25-39%, could adversely affect pharmaceutical imports, impacting the company’s financial condition and operations. The dynamic and unpredictable nature of these policy changes, coupled with potential investigations into national security risks associated with foreign-manufactured pharmaceutical ingredients, adds further uncertainty. As Allogene Therapeutics relies on global third-party suppliers for raw materials, increased tariffs may lead to higher research and development expenses, posing a material risk to their business prospects.

Overall, Wall Street has a Moderate Buy consensus rating on ALLO stock based on 10 Buys and 4 Holds.

To learn more about Allogene Therapeutics’ risk factors, click here.